Related Experiment Video
Updated: Feb 4, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
The Emerging Role of PCSK9 Inhibitors in Preventive Cardiology
Reynaria N Pitts1, Robert H Eckel1
1Charles A. Boettcher II Chair in Atherosclerosis, University of Colorado Anschutz Medical Campus, Aurora, CO, US.
Insights
New PCSK9 inhibitors offer hope for reducing cardiovascular disease (CVD) risk. These treatments effectively lower low-density lipoprotein cholesterol (LDL-C) in patients unresponsive to statins, potentially decreasing CVD events.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for coronary artery disease (CAD) and atherosclerotic cardiovascular disease (CVD).
- Residual CVD risk persists in patients with familial hypercholesterolemia or statin intolerance, even with lifestyle changes and statin therapy.
- PCSK9 protein plays a crucial role in regulating LDL receptor (LDL-R) degradation, impacting LDL-C levels.
Purpose of the Study:
- To investigate the efficacy of humanized monoclonal antibodies targeting PCSK9 for lowering LDL-C.
- To evaluate the potential of PCSK9 inhibitors in reducing residual cardiovascular risk.
- To assess the safety and tolerability of PCSK9 inhibitor therapy.
Main Methods:
- Development of humanized monoclonal antibodies (evolocumab, alirocumab, bocolicumab) that inhibit PCSK9.
- Administration of these antibodies to patients with elevated LDL-C.
- Monitoring of LDL-C levels, LDL-R expression, and adverse events.
Main Results:
- PCSK9 inhibitors increase LDL-R expression by approximately twofold.
- These antibodies achieve up to a 75% reduction in LDL-C levels.
- The effect of PCSK9 inhibitors is synergistic with statins, with local injection site reactions as the primary adverse effect.
Conclusions:
- Ongoing Phase III trials with PCSK9 inhibitors show promise for reducing CVD events and mortality in high-risk patients.
- PCSK9 inhibition represents a significant advancement in managing hypercholesterolemia and reducing residual cardiovascular risk.
- These novel therapies offer a new therapeutic avenue for patients unable to achieve adequate LDL-C lowering with current treatments.
Abstract:
Low-density lipoprotein cholesterol (LDL-C) is a most important risk factor for developing coronary artery disease (CAD) and other forms of atherosclerotic cardiovascular disease (CVD) and a major focus of CVD risk reduction with lifestyle and statins. Unfortunately residual risk of CVD remains in patients with familial hypercholesterolaemia and/or statin intolerance in whom adequate LDL-C lowering is not accomplished with lifestyle and statins. PCSK9 is a serine protease that binds the LDL receptor (LDL-R) and acts as a chaparone for endocytosis and shuttling the PCSK9-LDLR complex to lysosomes for degradation. In the absence of PCSK9 the LDLR-LDL-C complex dissociates and LDL-R is recycled back to the cell surface. Humanised monoclonal antibodies (evolocumab, alirocumab, bocolicumab) have been developed that increase LDL-R by ~2-fold and lower LDL-C by up to 75 percent. This effect is synergistic to that of statins with the only common adverse effect is a local injection site reaction. At present, ongoing Phase III CVD outcome trials with PCSK9 inhibitors offer promise that patients with LDL-C levels that remain elevated can decrease CVD events and related mortality.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Emerging Adulthood
Cancer Prevention
Some...
Introduction Cardiac Emergencies
Prevention of Further Absorption of Poison
Preventive Healthcare Services

